Our Roadmap

Join us on a mission to transform early disease detection. The TOBY™ platform is built to detect multiple conditions early, using a single, simple urine sample. While our long-term vision is to expand across various disease conditions, we recognize that groundbreaking change starts with focused, decisive steps.

Explore our development journey and see how we’re shaping the future of early detection.

Published Research

TOBY’s multicenter study evaluated urinary VOCs and AI for multi-cancer detection across 10 cancer types.

Read the study in Cancer Reports

Early detection starts with urine.

10 Cancers. One Test.

Breast Cancer

Cancer Cases: 12.5%

Lung Cancer

Cancer Cases: 12.2%

Colorectal Cancer

Cancer Cases: 10.7%

Prostate Cancer

Cancer Cases: 7.8%

Stomach Cancer

Cancer Cases: 6.0%

Bladder Cancer

Cancer Cases: 3.2%

Pancreatic Cancer

Cancer Cases: 2.7%

Cervical Cancer

Cancer Cases: 2.7%

Kidney Cancer

Cancer Cases: 2.4%

Ovarian Cancer

Cancer Cases: 1.7%

Be part of the movement for early detection via mass spectrometry of urine and artificial intelligence

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.